Trends in glucagon-like peptide 1 receptor agonist prescribing patterns.

Ukhanova M, Wozny JS, Truong CN, Ghosh L, Krause TM

The American journal of managed care1 Aug 2025Cited by 29 (Europe PMC)

PMID40829097DOI10.37765/ajmc.2025.89778PepBankPUB-40829097

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

01HumanNot a test of Semaglutide aloneObservational studyOther
In a US claims-based observational study of adults from 2018 to 2023, prescribing of semaglutides increased notably.
In plain wordsIn adult US claims records, semaglutide prescribing increased from 2018 to 2023.
Peptide
Semaglutide
Outcome
Increaseprescribing rate
Study
n: not reported in source
Outcome group
Patterns of use · Pharmacology
Source sentences
Summary
Prescribing of GLP-1 RA medications, particularly semaglutides, increased notably over the years, whereas dulaglutide, liraglutide, and exenatide use declined.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective, population-based, observational study using the Merative MarketScan Commercial Database and the Merative MarketScan Medicare Supplemental Database, which capture person-specific clinical utilization and expenditures.
Summary · context
We analyzed GLP-1 RA prescribing rates from 2018 to 2023, comparing semaglutide with other GLP-1 RAs and stratifying by diabetes and overweight/obesity indications.
Summary · context
The study included individuals 18 years or older with 12 months of continuous enrollment from 2018 to 2023, categorizing GLP-1 RA users into 4 groups based on diabetes and obesity/overweight diagnosis codes within a year of their index date.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4082909701
02HumanNot a test of Liraglutide aloneObservational studyOther
In a US claims-based observational study of adults from 2018 to 2023, liraglutide use declined.
In plain wordsIn adult US claims records, liraglutide use declined from 2018 to 2023.
Peptide
Liraglutide
Outcome
Decreaseprescribing rate
Study
n: not reported in source
Outcome group
Patterns of use · Pharmacology
Source sentences
Summary
Prescribing of GLP-1 RA medications, particularly semaglutides, increased notably over the years, whereas dulaglutide, liraglutide, and exenatide use declined.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective, population-based, observational study using the Merative MarketScan Commercial Database and the Merative MarketScan Medicare Supplemental Database, which capture person-specific clinical utilization and expenditures.
Summary · context
We analyzed GLP-1 RA prescribing rates from 2018 to 2023, comparing semaglutide with other GLP-1 RAs and stratifying by diabetes and overweight/obesity indications.
Summary · context
The study included individuals 18 years or older with 12 months of continuous enrollment from 2018 to 2023, categorizing GLP-1 RA users into 4 groups based on diabetes and obesity/overweight diagnosis codes within a year of their index date.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4082909702
03HumanNot a test of Liraglutide aloneObservational studyOther
In US adult claims records from 2018 to 2023, prescribing of pooled GLP-1 receptor agonist medications including liraglutide increased; this does not imply each drug increased.
In plain wordsIn adult US claims records, pooled GLP-1 drug prescribing including liraglutide increased over time; individual drugs could show different trends.
Peptide
Liraglutide
Outcome
IncreaseGLP-1 receptor agonist prescribing
Study
n: not reported in source
Outcome group
Patterns of use · Pharmacology
Source sentences
Summary
Prescribing of GLP-1 RA medications, particularly semaglutides, increased notably over the years, whereas dulaglutide, liraglutide, and exenatide use declined.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective, population-based, observational study using the Merative MarketScan Commercial Database and the Merative MarketScan Medicare Supplemental Database, which capture person-specific clinical utilization and expenditures.
Summary · context
We analyzed GLP-1 RA prescribing rates from 2018 to 2023, comparing semaglutide with other GLP-1 RAs and stratifying by diabetes and overweight/obesity indications.
Summary · context
The study included individuals 18 years or older with 12 months of continuous enrollment from 2018 to 2023, categorizing GLP-1 RA users into 4 groups based on diabetes and obesity/overweight diagnosis codes within a year of their index date.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4082909703
04HumanNot a test of Semaglutide aloneObservational studyOther
In US adult claims records from 2018 to 2023, prescribing of pooled GLP-1 receptor agonist medications including semaglutide increased; this does not imply each drug increased.
In plain wordsIn adult US claims records, pooled GLP-1 drug prescribing including semaglutide increased over time; individual drugs could show different trends.
Peptide
Semaglutide
Outcome
IncreaseGLP-1 receptor agonist prescribing
Study
n: not reported in source
Outcome group
Patterns of use · Pharmacology
Source sentences
Summary
Prescribing of GLP-1 RA medications, particularly semaglutides, increased notably over the years, whereas dulaglutide, liraglutide, and exenatide use declined.
3 context sentences(design, population, supporting numbers)
Summary · context
We conducted a retrospective, population-based, observational study using the Merative MarketScan Commercial Database and the Merative MarketScan Medicare Supplemental Database, which capture person-specific clinical utilization and expenditures.
Summary · context
We analyzed GLP-1 RA prescribing rates from 2018 to 2023, comparing semaglutide with other GLP-1 RAs and stratifying by diabetes and overweight/obesity indications.
Summary · context
The study included individuals 18 years or older with 12 months of continuous enrollment from 2018 to 2023, categorizing GLP-1 RA users into 4 groups based on diabetes and obesity/overweight diagnosis codes within a year of their index date.
In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.
Report a problemFND-4082909704

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 4Current
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 3
12 Oct 2026, 11:11 UTC
Study results updated
Version 2
9 Oct 2026, 03:06 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.